Navigation Links
How Candida albicans transforms from its normally benign form into life-threatening form
Date:10/4/2007

Researchers at the Agency for Science, Technology and Research's (A*STAR) Institute of Molecular and Cell Biology (IMCB) have discovered new molecular mechanisms that provide a more detailed understanding of how the normally benign Dr. Jekyll-like fungus known as Candida albicans transforms into a serious and often life-threatening Mr. Hyde-like form.

C. albicans can cause serious and potentially life-threatening infections in the mouth, blood and other tissues of people who are undergoing cancer chemotherapy or radiation treatments, or who have developed AIDS or other diseases that damage the immunity of the individual.

In two separate papers published last month in Developmental Cell and in August in the EMBO journal, the team of scientists led by Wang Yue, principal investigator at IMCB, have managed to reveal previously unknown mechanisms which are responsible for causing the infectious phase of C. albicans.

The fungus starts its 'attack' on a patient by changing its oval shape into a filamentous form, which has thin, threadlike appendages emerging from the cell body. Wang's team, who has been studying C. albicans for more than seven years, was responsible for identifying the master "controller" protein called Hgc1 in 20041.

This "controller" functions like a regulator and tells the fungus when to start the transformation from the harmless oval shape to the infectious filamentous form.

"One question remained, however - how does it activate the cellular machineries that determine the fungal cell shape?" said Wang.

Wang's team found the answer to this question in two proteins called Rga2 and Cdc11. They discovered that they each function like a switch on two different cellular machineries that normally determines cell shape. "The master regulator Hgc1 acts like the 'finger' that flips the switches to start the infection process," said Wang.

"Our findings have uncovered detailed molecular mechanisms which define how these two proteins interact with the master 'controller' to cause infections. This has opened new opportunities for us to investigate further into a new range of therapeutic targets for fungal infections," explained Wang.

In the same issue of Developmental Cell, the team's work was given an expert mention by a leading C. albicans researcher, Dr. Peter Sudbery, stating its importance in bringing awareness of the cellular processes that is necessary for C. albicans to transform to its infectious state.

In addition, the new knowledge of the detailed interaction of these proteins with other cellular machineries has also revealed critical information on how cells in general determine their shape, a fundamental question in biology as Rga2 and Cdc11 are also found in nearly all eukaryotic organisms.

Largely due to the AIDS pandemic in the last 25 years, the once nearly harmless and commensal fungus Candida albicans has become one of the most prevalent microbial pathogens in AIDS patients, causing life-threatening infections with high death rate, especially in infected children.


'/>"/>

Contact: Cathy Yarbrough
sciencematter@yahoo.com
858-243-1814
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Related medicine news :

1. Candidate vaccine to reduce hepatitis C viral load.
2. New Test Identifies Candidates For Cardiac Defibrillator
3. HIV-Positive Woman To Be Congress Candidate In Assam
4. Reservation For SC/ST Candidates Under 50% All India Quota
5. DBT And IAVI Forge Partnership To Develop “Next Generation” Vaccine Candidats
6. Republican Presidential Candidates Discuss Abortion, Stem Cells as Part of First Debate
7. DBT And IAVI Forge Partnership To Develop Next Generation Vaccine Candidates
8. Transformed Transforms Physician Centered Practice To Patient Centered One
9. Carriers With Alzheimers High Risk Gene Type Age Normally Until the Disease Strikes
10. Cannibalistic Signals Help Mammalian Embryos Develop Normally
11. Benign eye tumors being treated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance ... assistance to clients in southern Montana, is announcing a focused charity effort to ... The outreach programs offered by Zoo Montana provide students with current knowledge on ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... ... 27, 2017 , ... Excel Medical, the leader in Next-Generation ... of Executive Vice President, Sales and Marketing. Finnegan is a widely known industry ... sales leadership. He has received industry recognition for innovations and new approaches to ...
(Date:6/27/2017)... PA and London UK (PRWEB) , ... June 27, 2017 , ... ... applying to a clinical study is whether they can trust the sponsor to pay ... it is vital that sponsors and CROs establish payment strategies that encourage sites to ...
(Date:6/27/2017)... ... 27, 2017 , ... Salucro, the cloud-based payment platform that ... hospitals and provider groups, has announced that it will now offer Parasail’s payment ... a San Francisco health-finance startup that has launched a series of tech-based products ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)...  Eli Lilly and Company (NYSE: ... Phase 3 MONARCH 2 study showed that abemaciclib, ... combination with fulvestrant, significantly improved progression-free survival (PFS) ... with hormone-receptor-positive (HR+), human epidermal growth factor receptor ... or progressed after endocrine therapy (median PFS, 16.4 ...
(Date:5/30/2017)... May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... today announced that it will be presenting at the 7th annual ... PT. Erez Raphael , CEO, of DarioHealth will be giving ... be held on June 6th & 7th, 2017 at the Luxe ... small / micro-cap space. About ...
(Date:5/29/2017)... 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... enables the functional selection of stem cells, today provided ... first quarter ended March 31 st , 2017. ... in the first quarter of 2017," said Dr. Shai ... announced the treatment of the first blood cancer patient ...
Breaking Medicine Technology: